Nautilus Biotechnology Inc expected to post a loss of 15 cents a share - Earnings Preview

Nautilus Biotechnology

29/07/2025 14:21

Nautilus Biotechnology Inc NAUT.OQ NAUT.O is expected to  show no change in quarterly revenue when it reports  results on July 31 for the period ending June 30 2025

​LSEG's mean analyst estimate for Nautilus Biotechnology Inc is for a loss of 15 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $2.50, about 68.7% above its last closing price of $0.78

This summary was machine generated July 29 at 13:21 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)